November 21, 2026

Beximco Pharma launches new inhaler

Beximco Pharmaceuticals Ltd (BPL), the leading manufacturer of inhaler in the country, launched a new inhaler, Iprasol, in the local market recently.

bdnews24.com News Service

bdnews24.com

Published : 23 Jul 2005, 06:00 PM

Updated : 18 Aug 2022, 11:45 AM

Advisory: With photo Dhaka, July 24 (BDNEWS) - Beximco Pharmaceuticals Ltd (BPL), the leading manufacturer of inhaler in the country, launched a new inhaler, Iprasol, in the local market recently. Experts say adult asthma patients can use the new inhaler but further survey is required to administer it to children. According to them, Iprasol can also be useful for the treatment of chronic obstructive pulmonary disease (COPD). The experts' comments came at an asthma specialists' opinion-exchange meeting on Iprasol organised by the BPL at a local hotel on Saturday. A number of asthma specialists from across the country took part in the discussion on the newly-lunched inhaler. Prof Rashidul Hassan of National Institute of Diseases of the Chest & Hospital (NIDCH) said both adults and children can use Iprasol for COPD treatment. Moderating the discussion, Prof Mustafizur Rahman, director and head of the Department of Respiratory Medicine at the NIDCH, said Iprasol could also be used as an alternative to nebulisation. Iprasol, available in metered-dosed inhaler (MDI) form, is a combination of Salbutamol and Ipratropium. Rabbur Reza, executive director (marketing) of the BPL, was optimistic that Iprasol would meet patients' demand at an affordable price, available at Tk 230 apiece. The other leading inhalers of Beximco Pharma include Azmasol, Decomit, Bexitrol, Bexitrol-F, Aeronid and Ipramid. All BPL inhalers are produced at the company's MDI plant at Tongi, which is the lone plant that has been awarded with the authority to manufacture inhaler on behalf of Glaxosmithkline Plc (GSK), world's leading research-based pharmaceutical company. BDNEWS/2042 hrs
Related Stories